TREM1 and colitis: As support, in two murine models of dextran sodium sulfate-induced colitis, and colitis-associated azoxymethane-induced tumorigenesis, administration of the TREM-1 antagonist LP17 produces anti-inflammatory effects in the colon and decreases intestinal epithelial proliferation [43].